Biotech’s future won’t be won by a single business model. In this editorial, Anders Månsson breaks down the strengths and weaknesses of asset, platform, and service models—and argues that the real winners will be hybrids that blend all three to stay financeable, scalable, and resilient in tougher markets.

What makes a biotech partnership truly successful ? Beyond term sheets and deal structures, the strongest collaborations are built on trust, alignment, and a shared vision. Discover the human side of biotech partnering.